GFAP and Alzheimer disease: Concurrently, dual immunofluorescence and colocalization analysis of a complement anaphylatoxin component C3d with astrocytes (GFAP+, Figure S5A–C) showed a significant reduction in C3d‐GFAP colocalization in the AD brain treated with hNSC‐ and iMGL‐EV (mPFCs) compared to the vehicle‐treated AD group at 10 weeks post‐EV injections, indicating reduced astrocytic activation.